Complex Endometriosis Center

MOVING FORWARD

The CEC is proud to have participated in this research, which is now being applied to scientific studies on new molecules for the treatment of endometriosis.

This is a continuation of scientific work on a GnRH antagonist, Linzagolix, which CEC has already offered its patients in a pilot trial in 2018.

 

 

At 3 months, Linzagolix administration showed a clinically and statistically significant efficacy in reducing dysmenorhoea and intermenstrual pain.

The proportion of patients responding to dysmenorrhea was 73% in the treated group versus 23% in the placebo group.

This is a significant advance in the medical treatment of women suffering from endometriosis.